Participated · Series E · Jun 2026

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Participated · Series D · Jun 2023

Augmedics develops an AR-based navigation platform (branded Xvision) combining custom hardware and software to display digitized CT scans from a surgeon’s perspective. Its system, FDA-cleared in 2019 and commercially deployed in 2020, has been used in over 4,000 procedures and is installed in more than 70 U.S. hospitals. The platform can replace fluoroscopy in some non-invasive procedures and provides continuous intraoperative spine visualization in more invasive operations. The company emphasizes purpose-built hardware optimized for surgical use rather than off-the-shelf AR gear. Management plans to use new funding to build the next generation of the platform and accelerate commercial development while remaining focused on spinal applications. It has also received inbound interest for extensions into other musculoskeletal and cranial procedures that use CT/MRI imaging. Augmedics develops the xvision Spine System, the first and only FDA‑cleared augmented reality surgical image guidance system that lets surgeons visualize 3D spinal anatomy and navigate instruments while looking directly at the patient. The company received FDA 510(k) clearance in December 2019 and began U.S. sales in the second half of 2020. By year-end 2020 the system had been used in over 250 spinal surgeries. Augmedics plans to commercialize more broadly across the U.S. and into OUS markets, pursue CE certification for Europe, develop next‑generation products, and expand to new indications. Financially, the company has raised $63 million to date following a recent $36 million Series C and an earlier $21 million Series B. Augmedics develops the xvision Spine (XVS), an augmented reality surgical image-guidance system that enables surgeons to visualize a patient’s 3D spinal anatomy during surgery. XVS is designed to let surgeons accurately navigate instruments and implants while looking directly at the patient rather than a remote screen. The company received FDA 510(k) clearance and launched XVS in the U.S. in December 2019. The system is being used in renowned hospitals and surgical centers in the U.S. In June 2020 Augmedics completed a $15M Series B round that included staff investment and SAFE conversions. Leadership cited in the article includes founder and CEO Nissan Elimelech and President and CCO Tim Murawski. Augmedics develops the ViZOR, an augmented-reality surgical visualization system that projects a 3D image of a patient’s spine onto a surgeon’s retina in real time using proprietary see-through AR optics. The ViZOR is intended initially for minimally invasive spine surgeries to reduce operative time, radiation exposure and unnecessary repeat operations or hospitalizations. Augmedics plans to complete R&D and conduct pre-clinical and clinical trials of The ViZOR, and to pursue 510(k) clearance from the U.S. FDA. Future product development includes integrating sensors to collect surgical data and applying deep learning to provide suggestions, alerts and other intraoperative assistance. The company has received industry honors and previously raised seed financing from the TerraLab incubator (an incubator of the Israeli Innovation Authority). Financially, it recently secured an $8.3 million Series A to advance regulatory and commercialization efforts.

Participated · Equity · Feb 2022

Magnolia Medical develops, manufactures, and markets blood and bodily fluid collection devices designed to improve the accuracy, consistency, and predictability of critical laboratory tests. The company invented and patented the Initial Specimen Diversion Technique (ISDT™) and Device (ISDD®) for blood culture collection and contamination prevention. It has amassed an intellectual property portfolio with more than 100 issued method, apparatus, and design patents and over 70 patent applications pending. Led by CEO Greg Bullington, Magnolia Medical is FDA-cleared and intends to use new funding to fast-track innovations leveraging its IP to advance its mission to eliminate the misdiagnosis of sepsi. The company sells a device platform and continues to focus on reducing contamination and improving laboratory diagnostic reliability. Magnolia Medical Technologies, led by CEO Greg Bullington, develops, manufactures and markets innovative blood and bodily fluid collection and contamination-prevention devices for clinical laboratories. Its Steripath® Gen2 Initial Specimen Diversion Device® (ISDD®) has been adopted in hospitals across the U.S. to address blood culture contamination. The Steripath product is used to help eliminate blood culture contamination, reducing false positive diagnostic results for sepsis and inappropriate antibiotic use. Magnolia plans to develop and commercialize additional products that improve the accuracy and consistency of other important IVD tests, leveraging an extensive intellectual property portfolio built over the past decade. The company intends to use the Series C proceeds to scale market initiatives and advance its portfolio of blood and bodily fluid collection and contamination-prevention devices. Magnolia Medical is based in Seattle, WA. Magnolia Medical Technologies' core product is the SteriPath blood collection system, the only commercially available device described in the article as designed to eradicate false positive blood cultures. The company says SteriPath has reduced false positive results by an average of 93 percent in real‑world clinical environments across IDNs, managed care organizations and government hospitals. Magnolia develops a roadmap of additional devices intended to mechanically eliminate human errors that cause erroneous IVD results, improving patient safety and reducing hospital costs. The company emphasizes clinical and economic benefits, including reduced unnecessary antibiotic use and shorter patient stays. Proceeds from the recent financing will be used to accelerate SteriPath commercialization and support ongoing product development.

Participated · Series D · May 2021

Akili Interactive develops prescription digital therapeutics, including EndeavorRx, the first-and-only FDA‑cleared treatment delivered through a video game experience for children with ADHD. EndeavorRx is built on Akili’s Selective Stimulus Management Engine (SSME) and uses adaptive algorithms to target attentional control systems. The company plans to scale go-to-market efforts to bring EndeavorRx to families and healthcare professionals, expand its global footprint in ADHD and beyond, and advance a pipeline of prescription digital therapeutics for chronic and acute cognitive disorders. Akili emphasizes clinical validation, citing positive results in prospective randomized, controlled trials and extensive clinical studies. Financially, the company announced $160M in combined equity and debt financing—$110M Series D equity and a credit facility of up to $50M with Silicon Valley Bank—and reports total equity funding to date of $230M. The funding is intended to support commercialization, technology development, clinical research, and international expansion. Akili develops prescription digital medicines that embed targeted stimuli into immersive action video game experiences to treat conditions across neurology and psychiatry. Its lead program, AKL-T01 for pediatric ADHD, is under FDA review following positive pivotal study topline results announced in December 2017. If cleared, AKL-T01 would be the first prescription video game to treat a medical condition and the first prescription digital medicine for children with ADHD. The company has additional programs in Major Depressive Disorder, multiple sclerosis and various inflammatory diseases, and expects results from a Phase 2 MDD study and an MS pilot by the end of 2018. Akili is also developing complementary clinical monitors and measurement-based care applications. The company was founded by PureTech Health and is advancing its platform with recent equity financing. Akili Interactive develops prescription digital treatments that deliver therapeutic activity through action video game experiences. The company is building a broad pipeline of programs on its patented technology platform to treat cognitive deficits and symptoms across neurology and psychiatry, including ADHD, major depressive disorder, autism spectrum disorder and various inflammatory diseases. Its lead candidate is AKL‑T01 and it is also developing complementary clinical monitors and measurement‑based care applications. Akili was founded by PureTech Health and is led by CEO Eddie Martucci, Ph.D. The company used the financing to advance digital treatment candidates through regulatory milestones, prepare for commercial launch, and to broaden its product pipeline, including programs in depression and multiple sclerosis. Akili builds clinically validated cognitive treatments and assessments delivered through an action video‑game interface, based on its Project: EVO platform licensed from Dr. Adam Gazzaley at UCSF. The company is clinical‑stage and is conducting a pivotal STARS‑ADHD trial of Project: EVO in pediatric ADHD with plans to seek FDA approval if results are favorable. Akili has multiple clinical studies across ADHD, autism spectrum disorder, depression, Alzheimer’s disease, and traumatic brain injury, and has expanded into neurodegeneration indications including Parkinson’s disease, major depressive disorder, and multiple sclerosis. The platform is designed to target core neurological processing and can adapt difficulty in real time for remote use without physician calibration. Akili plans to use the new funds to support and expand clinical development into new areas, increase focus on neurodegeneration, and build out its commercial infrastructure as it nears market with late‑stage products. The company was founded by PureTech Health together with neuroscientists and game designers and has strategic partnerships with Pfizer and Autism Speaks and investment from Shire PLC. Akili develops mobile software-based treatments and monitors designed to function as action video games, targeting cognitive disorders with adaptive, medical-grade software. Its lead product candidate, Project: EVO, is licensed from Dr. Adam Gazzaley's lab at UCSF and was previously published as a Nature cover story. The platform targets cognitive interference processing and adapts difficulty in real time to allow wide-ranging ability levels to use the product without physician calibration or extra hardware. Akili is conducting multiple clinical trials across pediatric ADHD, autism spectrum disorder (in collaboration with Autism Speaks), depression, Alzheimer’s disease (in collaboration with Pfizer) and traumatic brain injury. A recent open-label pilot in pediatric ADHD showed improvements in attention, inhibition and working memory, and the company plans a large randomized pivotal study with results expected in 2017. The company announced $30.5 million in new equity investments to support further clinical development and to build commercial infrastructure toward potential FDA clearance and a planned product launch in 2017.

Participated · Equity · Jul 2020

Cardiva Medical is a privately held medical device company focused on transforming vascular closure with its VASCADE and VASCADE MVP systems. VASCADE has been PMA-approved by the FDA since 2013 and demonstrated a statistically significant reduction in access-site complications in the randomized RESPECT trial. VASCADE MVP is the only marketed vessel closure technology designed specifically for electrophysiology procedures and received PMA approval in late 2018 after the AMBULATE trial. The company announced a $45 million equity financing to support continued commercial expansion of these systems and to fund other clinical and operational initiatives. Cardiva targets the more than 5.5 million catheter-based coronary, peripheral, and electrophysiology procedures in the U.S. that require access-site closure each year. The company is headquartered in Santa Clara, California, and has received industry recognition including the Shingo Bronze Medallion. Cardiva Medical is a privately held medical device company headquartered in Santa Clara, California, focused on developing and commercializing vascular closure technologies. Its flagship product, the FDA‑approved and CE‑marked VASCADE Vascular Closure System, is commercially available in the United States and demonstrated a statistically significant reduction in access site complications in the randomized RESPECT study. The company is advancing an investigational mid‑bore vein closure system through the IDE AMBULATE trial, which targets 6–12 French access sheaths used in cardiac ablation and other procedures. AMBULATE is a prospective, multi‑center, randomized, controlled study enrolling 204 patients across U.S. sites to compare Cardiva's system to standard manual compression and to shorten time to ambulation. Cardiva reported a high rate of VASCADE sales growth and recently closed on an additional $11 million, bringing total equity and debt financing in the current round to $41 million. Proceeds will fund U.S. commercial expansion of VASCADE and support the AMBULATE trial. Cardiva Medical develops and commercializes the VASCADE Vascular Closure System. The company plans to use new funding to continue commercial expansion of VASCADE and to develop proprietary closure technologies. Cardiva reported a $30m equity financing led by affiliates of Luther King Capital Management, PTV Healthcare Capital and the Canepa Advanced Healthcare Fund. The company is led by President and CEO John Russell. VASCADE demonstrated a statistically significant reduction in access site complications in the prospective, randomized RESPECT clinical trial. The RESPECT study included 420 patients at 20 U.S. centers comparing VASCADE to manual compression for femoral arterial closure. Cardiva Medical develops and commercializes vascular closure technology designed to help the body heal itself following catheterization procedures. Its product line includes VASCADE, a vascular closure system, and the Catalyst II and Catalyst III devices for aiding manual compression. VASCADE received FDA approval in 2013 and CE marking in 2012; Catalyst II and III were cleared by the FDA in 2007 and 2009, respectively. The company says it is ramping up commercialization of its vascular closure products. To support that commercialization, Cardiva has taken on a senior secured credit facility to provide working capital. Cardiva is privately held, was founded in 2002, and is based in Sunnyvale, California. Cardiva Medical develops a vascular closure system and is based in Sunnyvale, California. Its vascular closure system received FDA approval in February. According to an SEC filing dated July 29, the company has raised nearly all of the $3.5 million it was seeking, with only $2,367 remaining to close the deal. About this time last year the company completed the third tranche of a Series 2 financing. The filing lists officers and directors including President and CEO Charles Maroney, founder and former CEO Augustine Lien, and Co‑Founder and VP of R&D Zia Yassinzadeh, among others. The company could not be reached for comment and the article does not disclose revenue, users, or investor details.